PGEN vs XERS: stock comparison and AI forecast
Precigen, Inc. (PGEN) and Xeris Biopharma Holdings, Inc. (XERS) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
PGEN Precigen, Inc.
- Price
- $4.22 +1.7% · 6M
- Market Cap
- $1.51B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
XERS Xeris Biopharma Holdings, Inc.
- Price
- $13.08 +105.3% · 6M
- Market Cap
- $2.38B
- P/E Ratio
- 218.0x
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- XERS is 1.6 times larger than PGEN by market capitalization ($2.38B against $1.51B).
- Over the last six months XERS returned +105.3% and PGEN +1.7%.
- XERS carries 7.68 times debt per unit of equity, against 1.53 times for PGEN.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | PGEN | XERS |
|---|---|---|
| Market Cap | $1.51B | $2.38B |
| P/E Ratio | – | 218.00x |
| P/B Ratio | 18.03x | 48.88x |
| EPS | $-0.23 | $0.06 |
| Book Value/Share | $0.23 | $0.27 |
| Revenue/Share | $0.23 | $2.02 |
| FCF/Share | $-0.21 | – |
Profitability & Margins
| Metric | PGEN | XERS |
|---|---|---|
| ROIC | -30.4% | 16.2% |
| Gross Margin | – | 87.4% |
| Operating Margin | -65.9% | 12.7% |
| EBT Margin | -241.6% | 2.5% |
| Tax Rate | -0.1% | 0.0% |
Financial Health
| Metric | PGEN | XERS |
|---|---|---|
| Current Ratio | 5.58x | 2.15x |
| Quick Ratio | 4.83x | 1.58x |
| D/E Ratio | 1.53x | 7.68x |
| Financial Leverage | 2.53x | 8.68x |
| Interest Coverage | 14.8x | 2.5x |
| Working Capital | $141M | $155M |
Cash Flow
| Metric | PGEN | XERS |
|---|---|---|
| Operating Cash Flow | -$73M | $74M |
| Free Cash Flow | -$74M | – |
| Capital Spending | -$1M | – |
| OCF Growth YoY | – | 597.5% |
| FCF/Sales | -88.7% | – |
| CapEx/Sales | 1.3% | – |
Operational Efficiency
| Metric | PGEN | XERS |
|---|---|---|
| Asset Turnover | 0.40x | 0.87x |
| Receivables Turnover | 0.9x | 5.4x |
| Inventory Turnover | – | 0.6x |
| Fixed Assets Turnover | 6.3x | 79.4x |
| Days Sales Outstanding | 420 days | 68 days |
| Days Inventory | – | 604 days |
| Payables Period | – | 63 days |
| Cash Conversion Cycle | – | 609 days |
Income Statement
| Metric | PGEN | XERS |
|---|---|---|
| Total Revenue | $84M | $368M |
| Operating Income | -$55M | $47M |
| R&D Expense | $61M | $38M |
| SG&A Expense | $136M | $226M |
| Cost of Goods Sold | – | $46M |
Dividend & Shareholder Information
| Metric | PGEN | XERS |
|---|---|---|
| Shares Outstanding | 358M | 182M |
PGEN vs XERS: stock comparison and AI forecast
Which is bigger, PGEN or XERS?
XERS is 1.6 times larger than PGEN by market capitalization ($2.38B against $1.51B).
Which stock performed better over the last six months, PGEN or XERS?
Over the last six months XERS returned +105.3% and PGEN +1.7%.
Which one does Intratio's AI model rank higher, PGEN or XERS?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.